Dear ISA members, colleagues and friends,

The COVID-19 pandemic has become a major health care challenge and we are concerned about the impact of SARS-CoV2 infection on patients with amyloidosis, as well as the impact of amyloidosis on the course of COVID-19.

In accordance to the ISA recommendations on the management of patients with systemic amyloidosis during the COVID-19 pandemic, we believe that data collection and observations made during this pandemic may be of immense help in the future.

For this reason, the ISA Board has started a small survey to gather information about the course of COVID-19 in patients with all the different types of systemic and localized amyloidosis. Thanks to the global network of our Society, we plan to collect data regarding the outcome of the two diseases together and share our results.

If you wish to participate, please complete the short questionnaire at the following link (If the link above does not work, try copying it in your web browser), and you will receive access to participate in the data collection.

https://redcap.smatteo.pv.it/redcap/surveys/?s=JKC4MTAYLX

Many thanks for your help.

With best regards,

Giovanni Palladini
ISA President